Introduction
============

Maternal obesity and gestational diabetes mellitus (GDM) create an intrauterine environment that promotes fetal overgrowth (Group HSCR, [@b25]; Catalano et al. [@b12]), altered body composition (Catalano et al. [@b12]; Uebel et al. [@b53]), and increased risk of childhood obesity (Crume et al. [@b14]). As the interface between maternal and fetal circulations, the placenta represents a vital determinant of fetal growth through its role in nutrient delivery to the fetus. Indeed, altered placental nutrient transport, in particular amino acid transport, is a common pathway which leads to pathological fetal growth resulting in a fetus that is either large for gestational age with increased placental amino acid transport (Jansson et al. [@b30]) or growth restricted in cases of decreased amino acid transport (Glazier et al. [@b22]; Jansson et al. [@b28]). It is now increasingly recognized that placental nutrient transport function is highly influenced by the maternal environment (Jansson et al. [@b29]; Aye et al. [@b6]; Gaccioli et al. [@b21]; Diaz et al. [@b18]).

Maternal obesity and GDM are conditions associated with chronic low-grade inflammation, resulting in increased levels of proinflammatory cytokines IL-6 and TNF-*α* in the maternal circulation (Ategbo et al. [@b4]; Aye et al. [@b8]) and the placenta (Roberts et al. [@b48]; Oliva et al. [@b45]). IL-6 and TNF-*α* have been previously shown to stimulate System A amino acid transporter activity in cultured primary human trophoblast cells (PHTs) of the term placenta (Jones et al. [@b31]) as well as in hepatocyte cell lines (Watkins et al. [@b56]; Goenner et al. [@b23]). Furthermore, placental System A activity is positively correlated with birth weight in women across a range of body mass indices (Jansson et al. [@b30]), suggesting a link between maternal adiposity, systemic inflammation, placental nutrient transport, and birth weight.

System A amino acid transporters mediate sodium-dependent uptake of small, neutral amino acids such as alanine, serine, and glutamine (Christensen et al. [@b13]). There are three System A isoforms, sodium-coupled neutral amino acid transporter (SNAT) 1, SNAT2, and SNAT4, encoded by the genes *Slc38a1*, *Slc38a2*, and *Slc38a4*, respectively (Broer [@b10]). All three SNAT isoforms are expressed in the maternal-facing microvillus membrane of the human placenta (Hatanaka et al. [@b26]; Wang et al. [@b55]; Desforges et al. [@b17]). SNAT1 and SNAT2 exhibit similar properties with regard to substrate specificities and affinities, whereas SNAT4 has a lower affinity for neutral amino acids and also transports cationic amino acids (Hatanaka et al. [@b27]; Kudo and Boyd [@b34]). Importantly, these transporters establish an intracellular gradient of neutral amino acids, which can then be used to drive the uptake of essential amino acids such as leucine through exchange mechanisms mediated by System L transporters (Verrey [@b54]).

In our previous study, IL-6 was shown to stimulate System A activity in primary human trophoblasts (PHTs) through STAT3-dependent regulation of the System A transporter SNAT2 (Jones et al. [@b31]). Additionally, System A transport activity in PHTs is also activated by TNF-*α* (Jones et al. [@b31]), although the underlying molecular mechanisms are currently unknown. In this study, we sought to identify the cellular signaling mechanisms by which TNF-*α* regulates System A amino acid transport. Mitogen-activated protein kinases (MAPKs) respond to a diverse array of stimuli including proinflammatory cytokines and growth factors, and regulate a number of cellular metabolic processes. There are three subfamilies of MAPKs that are activated by both inflammatory and mitogenic signals, extracellular signal-regulated kinases (Erk), c-Jun N-terminal kinases (JNK), and p38 MAPK. The objective of this study was to test the hypothesis that TNF-*α* regulates amino acid uptake in cultured PHT cells through a MAPK-dependent mechanism.

Materials and Methods
=====================

Study subjects and tissue collection
------------------------------------

Human placental tissue samples were collected from a total of 25 healthy women with normal term pregnancies who were scheduled for delivery by elective Cesarean section following written informed consent. Placental tissues were coded and de-identified relevant medical information was provided through the repository. This study was approved by the Colorado Multiple Institutional Review Board (COMIRB-14-1073). The early pregnancy (\<14 weeks gestation) body mass index of the women included in this study ranged from 20.3 to 29.8.

Primary human trophoblast cell culture and treatments
-----------------------------------------------------

Placental tissue was transported to the laboratory within 15 min of delivery, and PHT cells were isolated by trypsin digestion and Percoll purification as originally described (Kliman et al. [@b33]) with modifications (Roos et al. [@b49]; Aye et al. [@b5], [@b7]). Briefly, approximately 40 g of villous tissue was dissected free of decidua and blood vessels, washed in phosphate-buffered saline (PBS), and digested in trypsin (0.25%, Invitrogen, Carlsbad, CA) and DNAse I (Sigma-Aldrich, St. Louis, MO). Digests were then poured through 70-*μ*m cell filters (BD Bioscience, San Jose, CA) and cytotrophoblast cells purified over a discontinuous 10--70% Percoll gradient centrifugation. Cells which migrated between 35% and 55% Percoll layers were collected and cultured in 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) and Ham's F-12 nutrient mixture (Invitrogen) containing 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA), 50 *μ*g/mL gentamicin, 60 *μ*g/mL benzyl penicillin, and 100 *μ*g/mL streptomycin (Sigma-Aldrich), and incubated in a 5% CO~2~ humidified atmosphere at 37°C. Following 18 h of culture, attached PHT cells were washed twice in warmed Dulbecco's PBS and culture media was changed daily over 90 h. Functional and expression analyses were performed at 90 h when the cultured cytotrophoblast cells have differentiated into syncytiotrophoblasts.

At 66 h (total culture time), PHT cells were treated with recombinant human TNF-*α* (10 pg/mL, Sigma-Aldrich) or vehicle control (PBS) in culture media containing 1% FBS as described previously (Aye et al. [@b5]). We have chosen this concentration of TNF-*α* because it is within the physiological range of maternal circulating levels at term in normal and GDM women (Kirwan [@b32]; Cseh et al. [@b16]; Altinova et al. [@b1]; Saucedo et al. [@b51]), and produces a consistent effect on amino acid uptake. For pharmacological antagonism of p38 or Erk MAPK activity, PHT cells were treated with the p38 MAPK inhibitor SB203580, 10 μmol/L (SB, Cell Signaling Technology) or Erk MAPK inhibitor U0126, 0.1 μmol/L (U0, Cell Signaling Technology) for 30 min prior to TNF-*α* stimulation. All experiments were terminated at 90 h of culture. At this time, cell lysates were processed for RNA extraction or protein lysates, and amino acid uptake or cell viability assays were performed.

Small interfering RNA (siRNA) transfection
------------------------------------------

Cells were plated either at 2.75 million per 35-mm dish for RNA and protein analyses, or 2 million per well in a six-well plate for amino acid transport assays. Following 18 h of culture, PHT cells were transfected with 100 nmol/L of siRNA targeting p38 MAPK (Sigma-Aldrich, SASI_Hs01_00018467) or nontargeting Scrambled (Scr) siRNA (SIC001, Sigma-Aldrich) using Dharmafect2 transfection reagent (ThermoScientific, Waltham, MA, USA) according to the manufacturer's protocol and as reported previously (Aye et al. [@b7]).

Biochemical characterization and viability of primary human trophoblast cells
-----------------------------------------------------------------------------

To determine the effects of siRNA transfection or pharmacological treatments on trophoblast differentiation, human chorionic gonadotropin secretion into cell culture media was measured using a commercial ELISA kit according to the manufacturer's instructions (IBL-America, Minneapolis, MN).

The viability of PHTs following siRNA transfection or pharmacological treatments was determined by the ability of cultured cells to metabolize 4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) (van Meerloo et al. [@b42]). Briefly, PHT cells plated in 96-well plates were incubated with 1 mg/mL of MTT reconstituted in PBS for 4 h at 37°C, lysed with 10% SDS, and absorbance read at 570 nm.

Amino acid transport
--------------------

System A amino acid transport was determined by measuring Na^+^-dependent uptake of ^14^C-methyl-aminoisobutyric acid (MeAIB) and System L transport activity measured as 2-amino-2-norbornane-carboxylic acid (BCH)-inhibitable uptake of ^3^H-leucine (Leu), as described previously (Roos et al. [@b49]). Following treatment of PHTs as indicated above, cells plated in triplicate were washed three times in Tyrode's salt solution with or without Na^+^ (iso-osmotic choline replacement) prewarmed to 37°C. Cells were then incubated with Tyrode's salt solution (with Na^+^ or Na^+^-free with addition of 1 mmol/L BCH) containing ^14^C-MeAIB (final concentration 20 μmol/L) and ^3^H-Leu (final concentration 12.5 nmol/L) for 8 min. Transport was terminated by washing cells three times with ice-cold Tyrode's salt solution without Na^+^. Cells were then lysed in distilled water and the water was counted in a liquid scintillation counter. Protein content of lysed cells was determined using the Lowry method (Lowry et al. [@b41]). Transporter-mediated uptakes were calculated by subtracting uptake in Na^+^-free/BCH buffer (nonmediated uptake) from uptake in Na^+^-containing buffer (total uptake) and transport activity is expressed as pmol per mg of protein per minute (pmol/mg/min).

Reverse transcription and quantitative polymerase chain reaction (Q-PCR)
------------------------------------------------------------------------

Total RNA was extracted using TRIzol Reagent (Life Technologies, Carlsbad, CA). cDNA synthesis was performed using the High-Capacity RNA-to-cDNA kit (Life Technologies). Q-PCR for SNAT1, SNAT2, SNAT4, succinate dehydrogenase complex subunit A (SDHA), and TATA box-binding protein (TBP) was performed in triplicate on 0.2 *μ*g of total RNA reverse transcribed into cDNA using SYBR Select Master Mix (Life Technologies). PCR amplification and detection were performed on a Quant Studio 6 Flex Real-Time PCR system (Life Technologies) using the following primers: SNAT1 -- forward 5′--GTGTATGCTTTACCCACCATTGC--3′ and reverse 5′--GCACGTTGTCATAGAATGTCAAGT--3′; SNAT2 -- forward 5′--ACGAAACAATAAACACCA-CCTTAA--3′ and reverse 5′--AGATCAGAATT GGCACAGCATA--3′; SNAT4 -- forward 5′--TTGCCGCCCTCTTTGGTTAC--3′ and reverse 5′--GAGGACAATGGGCACAGTTAGT--3′; SDHA -- forward 5′--TACAAGGTGCGGATTGATGA--3′ and reverse 5′--CACAGTCAGCCTCGTTCAAA--3′; and TBP -- forward 5′--GTTCTGGGAAAATGGTGTGC--3′ and reverse 5′--GCTGGAAAACCCAACTTCTG--3′. Amplification of a single product was confirmed by melting curve analysis. The amplified transcripts were quantified using the relative standard curve method and normalized to the geometric mean of SDHA and TBP.

Western blot analyses
---------------------

Cells were harvested in radioimmunoprecipitation (RIPA) buffer (50 mmol/L Tris HCl, pH 7.4, 150 mmol/L NaCl, 0.1% SDS, 0.5% Na-deoxycholate, and 1% Triton X-100) containing protease inhibitors and phosphatase inhibitor cocktail 1 and 2 (1:100, Sigma-Aldrich). Protein concentrations were determined using the bicinchoninic acid assay as per the manufacturer's instructions using bovine serum albumin (BSA) as the standard (Thermo Scientific, Rockford, IL).

Equal amounts of protein (3 *μ*g) were loaded into each well and separated on Any KD Mini-Protean Tris Glycine Pre-cast gels (BioRad, Hercules CA). Separated proteins were then transferred onto polyvinylidene difluoride membranes (Thermo Scientific) and blocked with 5% blotting-grade blocker (BioRad) for 1 h. After washing in Tris-buffered saline containing 0.1% Tween (TBS-T), membranes were incubated in primary antibodies overnight at 4°C in TBS-T containing 2.5% BSA. Primary antibodies were diluted as follows: rabbit anti-phospho-Erk1/2 (Thr202/Tyr204), phospho-JNK1/2/3 (Thr183/Tyr185), phospho-p38 MAPK (Thr180/Tyr182), Erk, JNK, p38 MAPK, SNAT1, SNAT2, and SNAT4 at 1 *μ*g/mL; and mouse anti-*β*-actin at 0.2 *μ*g/mL.

The membranes were then washed and incubated with peroxidase-conjugated goat anti-rabbit (1:2000) or anti-mouse antibody (1:5000) in TBS-T with 2% BSA for 2 h at room temperature and visualized by enhanced chemiluminescence using ECL Western Blotting Substrate (Pierce). Resultant images were captured on a G:Box ChemiXL1.4 (Syngene, Cambridge, UK) and bands quantified using Image J software (imagej.nih.gov). Target protein expression was normalized to *β*-actin expression. For each target protein, the mean density of the control sample bands was assigned an arbitrary value of 1. To determine whether the treatments influenced *β*-actin expression, membranes were also stained for total protein using Amido Black Stain (Sigma) and target protein expression quantified as described previously (Lanoix et al. [@b37]). Results corrected for *β*-actin and total protein staining using Amido Black stain were not different (data not shown) and therefore only data obtained with *β*-actin normalization are given.

All antibodies were obtained from Cell Signaling Technology, with the exception of the SNAT isoforms. SNAT1 antibody was obtained from Sigma-Aldrich. SNAT2 antibody was generated as described in Ling et al. (Ling et al. [@b39]) and was received as a generous gift from Dr. V. Ganapathy and Dr. P. Prasad at the University of Georgia, Augusta. SNAT4 antibodies were produced in rabbits using the epitope YGEVEDELLHAYSKV in human SNAT4 (Eurogentec, Seraing, Belgium) and previously characterized in placental tissues and trophoblast cells (Desforges et al. [@b17]; Roos et al. [@b49]).

Data presentation and statistical analysis
------------------------------------------

All studies were repeated in primary cultures from 4 to 9 different placentas. Data are presented as mean + SEM. Statistical significance was determined either by Student's *t*-test or by repeated measures ANOVA followed by Bonferroni post hoc test. *P* \< 0.05 was considered significant. Statistical analysis and graph plotting were performed using Prism 5 software (Graph Pad, La Jolla, CA).

Results
=======

TNF-*α* stimulates System A amino acid transport
------------------------------------------------

System A activity was increased by approximately 50% following stimulation with 10 pg/mL of TNF-*α* (Fig.[1A](#fig01){ref-type="fig"}). This concentration is within the reported range for circulating concentrations of TNF-*α* (1--20 pg/mL) in normal healthy pregnant women and women with GDM (Cseh et al. [@b15]; Kirwan [@b32]; Altinova et al. [@b1]; Saucedo et al. [@b51]). System L-mediated uptake of leucine, on the other hand, was not affected by TNF-*α* (Fig.[1B](#fig01){ref-type="fig"}). These findings are consistent with previous reports demonstrating TNF-*α* regulation of System A, but not System L uptake activity in PHTs (Jones et al. [@b31]). On the basis of these findings, we have focused our studies on System A activity.

![System A and System L amino acid transport activity in TNF-*α*-treated primary human trophoblasts. (A) System A and (B) System L transport activity as measured by MeAIB and leucine uptake, respectively, after exposure to TNF-*α* (10 pg/mL) for 24 h. Data are represent as mean + SEM, *n* = 6. \**P* \< 0.05. Cnt, control; TNF-*α*, tumor necrosis factor-alpha.](phy20003-e12594-f1){#fig01}

Activation of MAPK pathways by TNF-*α* treatment
------------------------------------------------

In order to identify the mechanism(s) by which TNF-*α* regulates System A transport, we determined the effect of TNF-*α* on MAPK signaling activity. Treatment with TNF-*α* significantly increased the phosphorylation of Erk (Fig.[2A](#fig02){ref-type="fig"}) and p38 (Fig.[2B](#fig02){ref-type="fig"}), but not JNK MAPK (Fig.[2C](#fig02){ref-type="fig"}). TNF-*α* did not influence the total expression of Erk, p38, or JNK-MAPK proteins. On the basis of these findings, we targeted Erk and p38 MAPK to determine the involvement of these pathways in regulating trophoblast System A amino acid transport in response to TNF-*α*.

![Activation of mitogen-activated protein kinase (MAPK) pathways following TNF-*α* exposure. Phosphorylated and total protein expression of (A) Erk, (B) p38, and (C) JNK MAPK in primary human trophoblasts after exposure to TNF-*α* (10 pg/mL). Data are presented as mean + SEM, *n* = 4. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Cnt, control; TNF-*α*, tumor necrosis factor-alpha.](phy20003-e12594-f2){#fig02}

Pharmacological antagonism of p38 MAPK prevents TNF-*α*-mediated System A transport
-----------------------------------------------------------------------------------

Inhibition of Erk activity was achieved by targeting the upstream Erk kinases MEK1 and MEK2 using U0126 (Favata et al. [@b19]). U0126 significantly inhibited both basal and TNF-*α*-dependent Erk phosphorylation (Fig.[3A](#fig03){ref-type="fig"}). However, inhibition of Erk activity did not prevent TNF-*α*-mediated increase in System A activity (Fig.[4](#fig04){ref-type="fig"}). SB203580 inhibits p38 MAPK catalytic activity by binding to the ATP-binding site, but does not inhibit the phosphorylation of p38 MAPK by upstream kinases (Kumar et al. [@b35]). Consistent with these reports, SB203580 treatment did not decrease p38 MAPK phosphorylation, but instead increased its phosphorylation (Fig.[3B](#fig03){ref-type="fig"}). Nevertheless, SB203580 prevented further p38 MAPK phosphorylation when treated with TNF-*α* (Fig.[3B](#fig03){ref-type="fig"}). Inhibition of p38 MAPK activity by SB203580 also inhibited TNF-*α*-mediated System A transport (Fig.[4](#fig04){ref-type="fig"}), suggesting that p38 MAPK activation is required for TNF-*α*-dependent increase in System A activity. Treatment with the pharmacological antagonists did not impair MTT cell viability or trophoblast differentiation as determined by human chorionic gonadotropin (hCG) secretion (data not shown).

![Pharmacological antagonism of Erk and p38 MAPK activity. Primary human trophoblasts were treated with the pharmacological antagonists U0126 (Erk inhibitor, 0.1 μmol/L) or SB203580 (p38 inhibitor, 10 μmol/L) 30 min prior to treatment with TNF-*α* (10 pg/mL) for 24 h. Phosphorylated and total protein expression of (A) Erk and (B) p38 MAPK. Data are presented as mean + SEM, *n* = 4. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. ND, not detectable; Cnt, control; TNF-*α*, tumor necrosis factor-alpha; U0, U0126; SB, SB203580.](phy20003-e12594-f3){#fig03}

![System A uptake activity following treatment with TNF-*α* and Erk/p38 MAPK antagonists. Na^+^-dependent MeAIB uptake was measured in primary human trophoblasts following treatment with pharmacological antagonists U0126 (Erk inhibitor, 0.1 μmol/L) or SB203580 (p38 inhibitor, 10 μmol/L) MAPK, 30 min prior to exposure to TNF-*α* (10 pg/mL) for 24 h. Data are presented as mean + SEM, *n* = 9. \**P* \< 0.05, \*\**P* \< 0.01. Cnt, control; TNF-*α*, tumor necrosis factor-alpha.](phy20003-e12594-f4){#fig04}

p38 MAPK silencing inhibits TNF-*α* stimulation of System A transporter protein expression and activity
-------------------------------------------------------------------------------------------------------

To further establish the role of p38 MAPK in regulating System A amino acid transport, we silenced p38 MAPK expression using RNA interference. Compared to scrambled siRNA, transfection with p38 siRNA reduced p38 MAPK protein expression by approximately 50% (Fig.[5A](#fig05){ref-type="fig"}). In PHT cells transfected with scrambled siRNA, TNF-*α* stimulated System A transport activity, whereas knockdown of p38 MAPK inhibited TNF-*α*-mediated transport (Fig.[5B](#fig05){ref-type="fig"}). siRNA transfections did not influence cell viability or hCG secretion (data not shown).

![Effects of p38 MAPK silencing on System A transport activity. Primary human trophoblasts were transfected with p38 MAPK siRNA or scrambled siRNA controls. (A) p38 MAPK protein expression in Scr siRNA or p38 siRNA-transfected cells at 90 h of culture. Data are presented as mean + SEM, *n* = 4. (B) Na^+^-dependent MeAIB uptake (System A) activity was measured in Scr siRNA or p38 siRNA-transfected cells with/without TNF-*α* (10 pg/mL) treatment. Data are presented as mean + SEM, *n* = 5. \**P* \< 0.05, \*\**P* \< 0.01. Cnt, control; TNF-*α*, tumor necrosis factor-alpha; Scr, scramble; p38, p38 MAPK.](phy20003-e12594-f5){#fig05}

We then determined if the effects of p38 MAPK silencing were associated with decreased expression of System A amino acid transporter isoforms SNAT1, SNAT2, and SNAT4. TNF-*α* significantly increased SNAT1 and SNAT2 protein expression, but did not affect SNAT4 protein (Fig.[6A](#fig06){ref-type="fig"}). Silencing of p38 MAPK attenuated TNF-*α*-mediated increase in SNAT1 protein, whereas the increase in SNAT2 protein expression was completely prevented following p38 MAPK knockdown (Fig.[6A](#fig06){ref-type="fig"}). p38 MAPK silencing did not affect the basal protein expression of the SNAT isoforms (Fig.[6A](#fig06){ref-type="fig"}).

![Regulation of SNAT1, SNAT2, and SNAT4 protein and mRNA expression by p38 MAPK. Primary human trophoblasts were transfected with p38 MAPK siRNA or scrambled siRNA controls with/without TNF-*α* (10 pg/mL) exposure for 24 h. (A) SNAT1, SNAT2, and SNAT4 protein expression normalized to *β*-actin. Data are presented as mean + SEM, *n *= 4. (B) mRNA expression of SNAT1, SNAT2, and SNAT4 normalized to the geometric mean of SDHA and TBP mRNA. Data are presented as mean + SEM, *n* = 6. \**P* \< 0.05. Cnt, control; TNF-*α*, tumor necrosis factor-alpha; Scr, scramble; p38, p38 MAPK.](phy20003-e12594-f6){#fig06}

Interestingly, TNF-*α* stimulation did not alter the mRNA expression of SNAT1, SNAT2, or SNAT4 (Fig.[6B](#fig06){ref-type="fig"}). Moreover, p38 MAPK silencing also did not affect the mRNA expression of System A amino acid transporter isoforms (Fig.[6B](#fig06){ref-type="fig"}). Taken together, these findings strongly suggest that TNF-*α* regulates System A transport activity through p38 MAPK-dependent regulation of SNAT1 and SNAT2 protein expression.

Discussion
==========

Metabolic disorders of pregnancy such as obesity and GDM are characterized by a chronic low-grade inflammatory environment (Pantham et al. [@b46]). Proinflammatory cytokines play an important role in regulating placental transport of nutrients including fatty acids (Lager et al. [@b36]) and amino acids (Jones et al. [@b31]). Hence, understanding the molecular mechanisms by which cytokines modulate nutrient transport may aid in the development of therapeutic strategies to reduce the incidence of fetal overgrowth in obese and GDM pregnancies, and thus reduce the burden of pediatric obesity and the development of adult metabolic diseases.

In this study, we provide mechanistic evidence that TNF-*α* regulation of System A amino acid transport is dependent on p38 MAPK. Consistent with previous reports, TNF-*α* stimulated System A activity in cultured PHTs but did not affect System L activity (Jones et al. [@b31]). Our previous study established the requirement of STAT3 in IL-6-dependent regulation of System A activity. STAT3 can be activated by cytokines such as IL-6, and hormones including leptin and insulin, and therefore lies at the nexus of cytokine and growth factor responses. Similarly, we propose that MAPKs may also represent such a system whereby growth factors and proinflammatory cytokines coordinate cellular metabolic processes.

Studies in nontrophoblast cells are consistent with a role for Erk and p38 MAPK in the regulation of amino acid transport. For example, the adaptive increase in System A transport activity following amino acid starvation requires Erk MAPK activation in human fibroblasts (Franchi-Gazzola et al. [@b20]; Lopez-Fontanals et al. [@b40]), and both Erk and p38 MAPK antagonists inhibited glutamate and glucose transport in intestinal cell lines (Gould et al. [@b24]; Meng et al. [@b43]). Moreover, our previous study showed that silencing of p38 MAPK inhibited insulin-stimulated System A activity in PHTs (Aye et al. [@b7]). We therefore hypothesized that the increase in Erk and/or p38 MAPK would regulate the effects of TNF-*α* on System A transport activity in PHTs. While inhibition of Erk activity did not influence System A activity, p38 MAPK antagonism inhibited System A transport. In addition, silencing of p38 MAPK prevented the stimulatory effect of TNF-*α* on System A activity.

The effects of TNF-*α* and p38 MAPK on System A transport were associated with changes in the expression of SNAT1 and SNAT2 proteins but not their mRNA expression. In agreement with our findings, previous reports have also demonstrated SNAT2 regulation at the protein level. We recently showed that SNAT2 activity in PHTs is regulated at the posttranslational level by the mechanistic target of rapamycin (mTOR) (Rosario et al. [@b50]), and p38 MAPK has been shown to regulate the downstream activation of the mTOR target S6K1 (Casas-Terradellas et al. [@b11]). However, mTOR-dependent regulation of SNAT2 is mediated by trafficking of the transporter protein to the plasma membrane rather than total SNAT2 protein expression in cells (Rosario et al. [@b50]). Previous reports suggest that cellular levels of SNAT2 protein may be degraded by the ubiquitin proteasome system (Nardi et al. [@b44]), and p38 MAPK has been shown to promote protein stability by suppressing protein ubiquitination (Xie et al. [@b57]). Therefore, the possibility exists that p38 MAPK regulates SNAT2 protein stability in PHTs by inhibiting SNAT2 ubiquitination and proteasomal degradation.

TNF-*α* failed to stimulate System A activity in the presence of the p38 MAPK inhibitor SB203580, suggesting that TNF-*α* regulates this amino acid transport system mediated by p38 MAPK. Counterintuitively, SB203580 increased p38 MAPK phosphorylation, which has been reported in the literature previously (Kumar et al. [@b35]). For example, Kumar and coworkers showed a dose-dependent increase in p38 phosphorylation with SB203580 in a number of cell lines including human monocytic THP-1 cells, osteosarcoma MG63 and chondrocyte C20A4 cells (Kumar et al. [@b35]). Thus, the functional significance of phosphorylation of p38 MAPK at T180/Y182 is unclear. Importantly, however, using RNAi to knockdown p38 MAPK expression, we provide conclusive evidence that p38 MAPK mediates the effects of TNF-*α* on trophoblast amino acid transport.

The concentration of TNF-*α* used in this study reflects the upper range of circulating TNF-*α* levels in pregnant women at term (Cseh et al. [@b15]; Kirwan [@b32]; Altinova et al. [@b1]; Saucedo et al. [@b51]; Xu et al. [@b58]). Because the placenta abundantly produces cytokines, it is possible that the local concentrations of TNF-*α* in the intervillous space may be higher than systemic concentrations. However, we have chosen not to determine the effects of high TNF-*α* concentrations because it may trigger apoptosis (Smith et al. [@b52]) and/or impair trophoblast cell viability or endocrine function (Li et al. [@b38]; Pijnenborg et al. [@b47]), effects which are also likely to influence trophoblast System A activity.

The overall effects of inflammation on placental nutrient transport are complex and may vary on the degree and type of inflammation, the specific cytokines that are elevated, or even the type of transporter in question. Although our findings suggest that System A activity is stimulated by TNF-*α* or IL-6 (Jones et al. [@b31]) at concentrations characteristic of chronic metabolic disease (Xu et al. [@b58]; Pantham et al. [@b46]), in other situations such as infections or septic shock, the impact of acute inflammatory stress on placental nutrient transport may differ. For example, it has been proposed that the inflammatory response to placental malaria decreases System A transport activity and contributes to fetal growth restriction (Boeuf et al. [@b9]). High concentrations of TNF-*α* have also been reported to inhibit folic acid and methionine uptake in cultured trophoblasts (Araujo et al. [@b2],[@b3]). Furthermore, we recently reported that while IL-1*β* does not influence basal System A transport, it inhibited insulin-mediated System A activity (Aye et al. [@b5]). On the other hand, IL-1*β* stimulated System L activity in PHTs (Aye et al. [@b5]). From these studies, it is evident that complex interactions exist between cytokines and growth factors in regulating different placental nutrient transport systems.

Chronic low-grade inflammation associated with obesity and GDM may play an important role in the in utero programming of metabolic disease. This may, at least in part, be due to cytokine regulation of placental nutrient transport. However, the signaling pathways responsible have so far remained elusive. In this study, we have established p38 MAPK as a critical mediator of TNF-*α*-dependent System A amino acid transport in cultured PHTs. These in vitro findings provide mechanistic insight linking our previous observations in obese mothers of elevated maternal circulating levels of TNF-*α* (Aye et al. [@b8]), increased placental p38 MAPK activity (Aye et al. [@b8]), and increased amino acid transport associated with fetal overgrowth (Jansson et al. [@b30]).
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